Skip to content
Bored Studies
RecruitingPhase 3

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

Psoriasis Research Institute of Guangzhou · NCT07426120

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–70 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
300
US sites recruiting
1
Study start
February 1, 2026
Record last updated
February 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to learn if a botanical Total Coumarin topical cream (TC Cream) works to treat psoriasis in adults. It will also learn about the safety of the topical TC Cream. The main questions it aims to answer are:

  • Does TC Cream improve the psoriasis disease symptoms?
  • What medical problems do participants have when applying TC Cream?
  • Does TC Cream improve the quality of life of psoriasis patients? Researchers will compare TC Cream to a placebo cream (a look-alike cream that contains no active drug) to see if TC Cream works to treat psoriasis.

Participants will

  • Topically apply the TC Cream or a placebo cream twice daily every day to affected skin for 8 weeks
  • Visit the clinic once every 2 weeks for checkups and tests
  • Keep a diary of their symptoms and their diseased skin conditions during the application of the topical cream

Being studied: Total coumarin (TC) cream; Vehicle cream

Conditions: Psoriasis Vulgaris; Topical Administration; Phase III

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age of 18-70 years old. Both men and women, and members of all races and ethnic groups
  • Consistent with the diagnostic criteria of stable phase psoriasis vulgaris, and have at least two target lesions suitable for evaluation
  • Women of childbearing age must be using birth control strategies defined by one of the following: 1) a barrier method (condom) and/or 2) oral contraceptives, during the 8-week study period.
  • ISGA score ≥ 2 (at least mild severity)
  • BSA (stable stage group): 1%≤ to ≤20%
  • Signed a written informed consent document
  • No additional exposure to the sun

Exclusion Criteria

  • Subjects in pregnancy, preparing for pregnancy, or breastfeeding
  • History of hyperergic or photosensitivity
  • History of complicated cardiovascular diseases, cerebrovascular diseases, severe primary diseases of the hepatic, kidney, and hematopoietic system, or patients with psychiatric disorders
  • History of photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosa
  • Within 4 weeks prior to randomization, patients have taken treatment with the following approved or investigational psoriasis therapies on the target lesions:
  • Topical treatments
  • PUVA, UVB, or Grenz ray therapy.
  • Any systemic treatments other than biologicals with a possible effect on psoriasis (e.g., corticosteroids, vitamin D analogues, hydroxycarbamide, azathioprine, methotrexate, cyclosporine, other immunosuppressants).
  • Any types of other investigational therapies for psoriasis
  • Within 3 months prior to randomizations, patients have taken systemic treatments with retinoids or biological therapies (marketed or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab).
  • Planned initiation of, or changes to, concomitant medications that could affect psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the study.
  • History of allergic reactions attributed to compounds of similar chemical or biologic compositions to Coumarins.

Recruiting US locations

  • Department of Dermatology, SUNY Downstate Health Sciences University

    New York, NY 11203

    Site contact: Wei-Li Lee, PhD · +1-(718) 270-1910 · Wei-Li.Lee@downstate.edu

Study contacts (from the official record)

  • Jiang Yang, MSc, PhD · +1-(608)-772-1251 · terence0731@gmail.com
All dermatology studies in New York →
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in… (NCT07426120) | Bored Studies